Mutational dynamics between primary and relapse neuroblastomas

Nature Genetics

Volumn 47, Issue 8, 2015, Pages 872-877

  Schramm, Alexander ^a   Köster, Johannes ^a,k   Assenov, Yassen ^b   Althoff, Kristina ^a   Peifer, Martin ^c   Mahlow, Ellen ^a   Odersky, Andrea ^a   Beisser, Daniela ^a   Ernst, Corinna ^a   Henssen, Anton G ^a,k,m   Stephan, Harald ^a   Schröder, Christopher ^a   Heukamp, Lukas ^d,k,l   Engesser, Anne ^e   Kahlert, Yvonne ^e   Theissen, Jessica ^e   Hero, Barbara ^e   Roels, Frederik ^e   Altmüller, Janine ^e,f   Nürnberg, Peter ^c,f   Astrahantseff, Kathy ^g   Gloeckner, Christian ^d   De Preter, Katleen ^h   Plass, Christoph ^b   Lee, Sangkyun ⁱ   Lode, Holger N ^j   Henrich, Kai Oliver ^b   Gartlgruber, Moritz ^b   Speleman, Frank ^h   Schmezer, Peter ^b   Westermann, Frank ^b   Rahmann, Sven ^a,i   Fischer, Matthias ^c,e   Eggert, Angelika ^b,g   Schulte, Johannes H ^a,b,g   more..

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d NEO New Oncology GmbH   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ TU DORTMUND UNIVERSITY   (Germany)

^j UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l Institute for Hematopathology   (Germany)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHD5 PROTEIN; DNA; K RAS PROTEIN; MESSENGER RNA; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 14; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CHD5 PROTEIN, HUMAN; DNA HELICASE; DOCK8 PROTEIN, HUMAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HIPPO PROTEIN, HUMAN; NERVE PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; PTPN14 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CELL INTERACTION; CHROMOSOME 9P; CHROMOSOME LOSS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; ONCOGENE H RAS; PRIMARY NEUROBLASTOMA; PRIORITY JOURNAL; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; COPY NUMBER VARIATION; DNA MICROARRAY; DNA SEQUENCE; EXOME; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; MUTATION; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA HELICASES; EXOME; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; NEOPLASM RECURRENCE, LOCAL; NERVE TISSUE PROTEINS; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84938278368     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3349     Document Type: Article

References (44)

1. Park, J.R., Eggert, A. & Caron, H. Neuroblastoma: Biology, prognosis, and treatment. Hematol. Oncol. Clin. North Am. 24, 65-86 (2010).
2. Cohn, S.L. et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J. Clin. Oncol. 27, 289-297 (2009).
3. Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E. & Bishop, J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121-1124 (1984).
4. Schulte, J.H. et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin. Cancer Res. 17, 5082-5092 (2011).
5. Sausen, M. et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 45, 12-17 (2013).
6. Pugh, T.J. et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279-284 (2013).
7. Cheung, N.-K.V. et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. J. Am. Med. Assoc. 307, 1062-1071 (2012).
8. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
9. Mossé, Y.P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
10. Schleiermacher, G. et al. Emergence of new ALK mutations at relapse of neuroblastoma. J. Clin. Oncol. 32, 2727-2734 (2014).
11. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
12. Cobrinik, D. et al. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases. Genes Chromosom. Cancer 52, 1150-1166 (2013).
13. Vandesompele, J. et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosom. Cancer 23, 141-152 (1998).
14. Zhang, Q. et al. Combined immunodeficiency associated with DOCK8 mutations. N. Engl. J. Med. 361, 2046-2055 (2009).
15. Belle, L. et al. The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking. Sci. Signal. 8, ra18 (2015).
16. Molenaar, J.J. et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589-593 (2012).
17. Theissen, J. et al. Heterogeneity of the MYCN oncogene in neuroblastoma. Clin. Cancer Res. 15, 2085-2090 (2009).
18. Shukla, N. et al. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin. Cancer Res. 18, 748-757 (2012).
19. Koyama, H. et al. Mechanisms of CHD5 inactivation in neuroblastomas. Clin. Cancer Res. 18, 1588-1597 (2012).
20. Fujita, T. et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl. Cancer Inst. 100, 940-949 (2008).
21. Fischer, A., Vázquez-Garciá, I., Illingworth, C.J. & Mustonen, V. High-definition reconstruction of clonal composition in cancer. Cell Rep. 7, 1740-1752 (2014).
22. Luo, Y. et al. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 147, 418.e8-429.e8 (2014).
23. Wiestler, B. et al. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-oncol. 16, 1630-1638 (2014).
24. Miyamoto, Y. & Yamauchi, J. Cellular signaling of Dock family proteins in neural function. Cell. Signal. 22, 175-182 (2010).
25. Griggs, B.L., Ladd, S., Saul, R.A., DuPont, B.R. & Srivastava, A.K. Dedicator of cytokinesis 8 is disrupted in two patients with mental retardation and developmental disabilities. Genomics 91, 195-202 (2008).
26. Vinci, G. et al. Association of deletion 9p, 46, XY gonadal dysgenesis and autistic spectrum disorder. Mol. Hum. Reprod. 13, 685-689 (2007).
27. Simon, T. et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials. Pediatr. Blood Cancer 56, 578-583 (2011).
28. Shao, D.D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184 (2014).
29. Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185-197 (2014).
30. Lin, L. et al. The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies. Nat. Genet. 47, 250-256 (2015).
31. Su, X., Zhang, L., Zhang, J., Meric-Bernstam, F. & Weinstein, J.N. PurityEst: Estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics 28, 2265-2266 (2012).
32. Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104-1110 (2012).
33. Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933-936 (2013).
34. Köster, J. & Rahmann, S. Snakemake-a scalable bioinformatics workflow engine. Bioinformatics 28, 2520-2522 (2012).
35. Theissen, J. et al. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma. Genes Chromosom. Cancer 53, 639-649 (2014).
36. Oakes, C.C. et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 4, 348-361 (2014).
37. Teschendorff, A.E. et al. A ?-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics 29, 189-196 (2013).
38. Assenov, Y. et al. Comprehensive analysis of DNA methylation data with RnBeads. Nat. Methods 11, 1138-1140 (2014).
39. Kocak, H. et al. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. Cell Death Dis. 4, e586 (2013).
40. Saitou, N. & Nei, M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406-425 (1987).
41. Boc, A., Diallo, A.B. & Makarenkov, V. T-REX: A web server for inferring, validating and visualizing phylogenetic trees and networks. Nucleic Acids Res. 40, W573-W579 (2012).
42. Schulte, J.H. et al. Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA-and TrkB-expressing neuroblastomas. Oncogene 24, 165-177 (2005).
43. Althoff, K. et al. miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int. J. Cancer 136, 1308-1320 (2015).
44. Otto, T. et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15, 67-78 (2009).